SAN DIEGO–Illumina, Inc. (NASDAQ:ILMN – News) today announced the appointment of Fredrick Clerie as Vice President of Quality Assurance and Regulatory Affairs reporting to Joel McComb, Senior Vice President and General Manager of Illumina’s Life Sciences Business Unit. In this newly created role, Fredrick will be responsible for managing and enhancing Illumina’s comprehensive Quality systems strategy to support the development, manufacture, and distribution of products serving the research and molecular diagnostic markets. Prior to joining Illumina, Fredrick served as Vice President of Global Quality Assurance and Regulatory Affairs for the Diagnostics Division of Bayer HealthCare, now Siemens Diagnostics. Under Fredrick’s leadership, Bayer HealthCare’s Diagnostics Division successfully obtained Premarket Approvals (PMA) for five automated infectious disease assays. Fredrick’s previous role was Vice President of Quality Assurance for the Laboratory Testing Segment (LTS) of Bayer HealthCare. During his three years at LTS, Fredrick successfully managed 13 Food and Drug Administration (FDA) inspections, the majority of which concluded with no report of any observation or non-conformance. He also served as the lead representative in direct negotiations with the FDA’s Center for Devices and Radiological Health (CDRH), which resulted in shortened PMA review periods for hepatitis assays. From 1992 to 2001 Fredrick held multiple positions at Bayer Diagnostics, most notably as Director of Regulatory Affairs. In this role, Fredrick was responsible for the global expansion of the Regulatory Affairs function. He also led pre-PMA meetings with both the Center for Biologics Evaluation and Research and the CDRH related to Bayer’s commercialization initiative for automated hepatitis and HIV assays. Prior to this role, Fredrick was Director of Business Development, where he played a key role in negotiating alliances with partners worldwide, and identified potential alliances that enhanced the performance of both the Chemistry and Immunodiagnostics Business Units for Bayer Healthcare. Fredrick earned a B.A. in Biology and Chemistry from Greenville College and a M.S. in Biochemistry from the University of Illinois. “Fredrick brings to Illumina a wealth of knowledge in the field of Quality Assurance and Regulatory Affairs,” said Joel McComb. “His diverse career history and experience with rapidly commercializing new technologies will help us prepare for entering the molecular diagnostics market.” About Mr. Clerie’s Compensation The Company granted an option to purchase 56,000 shares of Illumina’s common stock to Mr. Clerie as part of his inducement to join the company. The option was granted by the Company’s compensation committee pursuant to NASDAQ Marketplace Rule 4350(i)(1)(A)(iv) and under Illumina’s New Hire Stock and Incentive Plan, which was approved by Illumina’s Board of Directors on January 29, 2008. This option has the following terms: an exercise price equal to the closing fair market value of Illumina’s common stock on the grant date, a ten-year term and vesting over four years with 25 percent of the option vesting one year from the grant date and 1/48th of the option vesting monthly thereafter. The grant date for this option is June 23, 2008. About Illumina Illumina (www.illumina.com) is a leading developer, manufacturer, and marketer of next-generation life-science tools and integrated systems for the large-scale analysis of genetic variation and biological function. Using our proprietary technologies, we provide a comprehensive line of products and services that currently serve the sequencing, genotyping, and gene expression markets, and we expect to enter the market for molecular diagnostics. Our customers include leading genomic research centers, pharmaceutical companies, academic institutions, clinical research organizations, and biotechnology companies. Our tools provide researchers around the world with the performance, throughput, cost effectiveness, and flexibility necessary to perform the billions of genetic tests needed to extract valuable medical information from advances in genomics and proteomics. We believe this information will enable researchers to correlate genetic variation and biological function, which will enhance drug discovery and clinical research, allow diseases to be detected earlier, and permit better choices of drugs for individual patients. “Safe Harbor” Statement under the Private Securities Litigation Reform Act of 1995: this release may contain forward-looking statements that involve risks and uncertainties. Among the important factors that could cause actual results to differ materially from those in any forward-looking statements are Illumina’s ability (i) to integrate effectively our recent acquisition of Solexa, Inc., (ii) to develop and commercialize further our BeadArray™, VeraCode®, and Solexa® technologies and to deploy new sequencing, gene expression, and genotyping products and applications for our technology platforms, (iii) to manufacture robust microarrays and Oligator® oligonucleotides, (iv) to integrate and scale our VeraCode technology, together with other factors detailed in our filings with the Securities and Exchange Commission including our recent filings on Forms 10-K and 10-Q or in information disclosed in public conference calls, the date and time of which are released beforehand. We disclaim any intent or obligation to update these forward-looking statements beyond the date of this release.